Switch to Eylea reduces fluid improves visual acuity in eyes with wet AMD

Fluid was reduced and visual acuity was improved in eyes with neovascular age-related macular degeneration that received Eylea after multiple intravitreal injections of Avastin or Lucentis, according to a study.The retrospective study included 31 eyes of 31 patients with neovascular AMD who responded poorly to Lucentis (ranibizumab 0.5 mg, Genentech) and/or Avastin (bevacizumab 1.25 mg, Genentech) and were switched to Eylea (aflibercept 2 mg, Regeneron).